Efficacy of Galium-68 DOTATATE PET/CT in the Detection of Metastasis Rate of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Document Type: Original Article

Authors

1 Department of Nuclear Medicine, Gazi Yasargil Training and Research Hospital. Diyarbakir, Turkey

2 Department of Nuclear Medicine, Firat University Medical Faculty. Elazig, Turkey

Abstract

Objective(s): The aim of this study was to determine metastasis rate in patients with well-differentiated grade1 (G1) and grade 2 (G2) gastroenteropancreatic neuroendocrine tumors (GEP NETs) using the gallium-68 DOTATATE positron emission tomography/computed tomography (68Ga-DOTATATE PET/CT). This study was also targeted toward investigating the relationship of maximum standardized uptake value (SUVmax) with mitotic count, histological grade, and Ki-67 index.
Methods: This retrospective study included 38 patients (i.e., 17 males and 21 females) with G1 or G2 GEP NETs who underwent 68Ga-DOTATATE PET/CT in Diyarbakir Gazi Yasargil training and research hospital between November 2014 and March 2018. The patients had at least one positive lesion that was approved by two nuclear medicine specialists with a minimum of 10 years of experience.
Results: The median age of the patients was 50 years (age range: 27-80 years), and their mean age was 52±15 years. Out of 38 patients, 1 (2.6%), 2 (5.2%), 2 (5.2%), 3 (7.8%), 10 (28.5%), and 19 (50%) patients had primary hepatic, primary mesenteric, colon, duodenal, gastric, and pancreatic NETs, respectively. In addition, the liver metastasis, local lymph node invasions, distant lymph node metastasis, bone metastasis, peritoneal involvement, and lung metastasis were observed in 42%, 21%, 15.7%, 13%, 7.8%, and 5% of the cases, respectively. The SUVmax median values of G1 and G2 tumors were 9.45 (range: 4.2-43.6) and 34.9 (range: 4.1-103), respectively (P=0.003). The Ki-67 index showed a negative correlation with the SUVmax value of the liver metastases and the highest SUVmax value (P=0.001 and P=0.002, respectively). There was also a negative correlation between mitosis count and the highest SUVmax value (P=0.011).
Conclusion: Based on the findings, although [68Ga]DOTATATE PET/CT is successfully used to diagnose primary GEP NETs and their metastases, the SUVmax value obtained from DOTATATE PET/CT showed a negative correlation with Ki-67 and mitotic count.

Keywords

Main Subjects


  1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97:934–959.
  2. Kim JY, Hong SM, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol 2017; 29:11-16.
  3. Falconi M, Plöckinger U, Kwekkeboom DJ, Manfredi R, Korner M, Kvols L,et al. Well-differentiated pancreatic nonfunctioning tumors/ carcinoma. Neuroendocrinology 2006; 84:196–211.
  4. Basuroy R, Srirajaskanthan R, Ramage JK. A multimodal approach to the management of neuroendocrine tumour liver metastases. Int J Hepatol 2012; 2012:819193.
  5. Tirosh A, Kebebew E. The utility of 68Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors. Future Oncol 2018; 14:111-122.
  6. Jaï􀇅s P, Terris B, Ruszniewski P, LeRomancer M, Reyl-Desmars F, Vissuzaine C, Cadiot G, et al. Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours. Eur J Clin Invest 1997; 27: 639–644.
  7. Krenning EP, Bakker WH, Breeman WA, Kooij PP, Reubi JC, Koper JW, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989; 1:242–244.
  8. Deppen SA, Liu E, Blume JD, Clanton J, Shi C, Jones- Jackson LB, et al. Safety and Efficacy of 68Ga- DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. J Nucl Med 2016; 57, 708–714.
  9. Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, et al. Prospective Study of 68Ga- DOTATATE Positron Emission Tomography/ Computed Tomography for Detecting Gastro-Entero- Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol 2016; 34: 588–596.
  10. Cuccurullo V, Faggiano A, Scialpi M, cascini GL, Piunno A, Catalano O, et al. Questions and answers: what can be said by diagnostic imaging in neuroendocrine tumors? Minerva Endocrinol 2012; 37: 367–377.
  11. Kwekkeboom D, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs, J Nucl Med 2005; 46: 62–66.
  12. Geijer H, Breimer LH. Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2013; 40:1770–1780.
  13. Kim JY, Hong SM. Recent updates on neuroendocrine tumors from the gastrointestinal and pancreatobiliary tracts. Arch Pathol Lab Med 2016; 140: 437–448.
  14. Cross SS, Start RD, Smith JH. Does delay in fixation affect the number of mitotic figures in processed tissue? J Clin Pathol 1990; 43:597–599.
  15. Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogeneous and includes both well-differentiated and poorly differentiated neoplasms. Am J Surg Pathol 2015; 39:683–690.
  16. Kaewput C, Suppiah S, Vinjamuri S. Correlation between Standardized Uptake Value of 68Ga-DOTA-NOC Positron Emission Tomography/Computed Tomography and Pathological Classification of Neuroendocrine Tumors. World J Nucl Med 2016; 17:34-40.
  17. Naswa N, Sharma P, Gupta SK, Karunanithi S, Reddy RM, Panecha M et al. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: Competitive or complimentary? Clin Nucl Med. 2014; 39:27–34.
  18. Frilling A, Giele H, Vrakas G, Reddy S, Macedo R, Al- Nahhas A, et al. Modified liver-free multivisceral transplantation for a metastatic small bowel neuroendocrine tumor: a case report. Transplant Proc 2015; 47:858–862.
  19. Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga- DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer 2008; 112: 2447–2455.
  20. Schraml C, Schwenzer NF, Sperling O, Aschoff P, Lichy MP, Müller M, et al. Staging of neuroendocrine tumours: comparison of [(68)Ga]DOTATOC multiphase PET/CT and whole-body MRI. Cancer Imaging 2013; 13:63–72.
  21. Albanus DR, Apitzsch J, Erdem Z, Erdem O, Verburg FA, Behrendt FF, et al. Clinical value of (68)Ga- DOTATATE-PET/CT compared to stand-alone contrast-enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumors (NET). Eur J Radiol 2015; 84:1866–1872.